TREM2 and early-onset autosomal dominant Alzheimer disease: After the discovery of TREM2 mutations the study of a new target drug has been started (A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease - Full Text View - ClinicalTrials.gov, NCT04592874).